With partners Complement Pharma is continuous developing. Recently the team successfully added a new transgenic model to the spectrum.
As Complement Pharma is a development company, the work in the Company focuses on strengthening the data showing the preferred position of C6 for complement targeted treatment of neurodegeneration.
Furthermore, Complement Pharma is expanding the number of and the diversity of experimental disease models to possibly expand the clinical portfolio.